Screener
Ionis Pharmaceuticals IONS Income Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $267.95M-40.7% | $246.09M+87.0% | $203.33M-10.3% | $156.72M+17.1% | $452.05M+101% | ||
| $2.74M-34.0% | $2.98M+104% | $7.96M+108% | $2.34M+118% | $4.15M-0.3% | ||
| $265.21M-40.8% | $243.11M+86.8% | $195.37M-12.3% | $154.38M+16.3% | $447.9M+103% | ||
| 99%-0.1pp | 98.8%-0.1pp | 96.1%-2.2pp | 98.5%-0.7pp | 99.1%+0.9pp | ||
| —— | —— | $228.9M+1.6% | $228.9M+1.6% | $228.9M+1.6% | ||
| $150.4M+66.0% | $150.36M+97.2% | $130.19M+47.8% | $96.81M+57.1% | $90.62M+39.2% | ||
| $370.24M+18.6% | $363.52M+30.5% | $417.79M+23.8% | $316.9M+12.2% | $312.23M+7.2% | ||
| -$102.29M-173% | -$117.42M+20.0% | -$214.46M-93.5% | -$160.18M-7.8% | $139.82M+312% | ||
| -38.2%-69.1pp | -47.7%+63.9pp | -105.5%-56.6pp | -102.2%+8.9pp | 30.9%+60.3pp | ||
| $4.62M+12.3% | $5.16M+25.6% | $4.83M+15.2% | $4.21M+1.2% | $4.11M-8.4% | ||
| $987K+868% | -$456K-198% | -$16.29M-5,287% | $363K+156% | $102K-83.3% | ||
| -$113.38M-192% | -$92.31M+37.1% | -$227.92M-113% | -$128.39M+10.9% | $123.53M+287% | ||
| $1.26M+6,420% | $218K+87.9% | $1.48M+155% | $213K+106% | -$20K-131% | ||
| -$0.69-199% | -$0.56+39.8% | -$1.41-114% | -$0.80+15.8% | $0.70+256% | ||
| -$98.16M-169% | -$113.46M+21.2% | -$210.56M-94.7% | -$157.31M-8.0% | $142.68M+326% | ||
| -36.6%-68.2pp | -46.1%+63.3pp | -103.6%-55.8pp | -100.4%+8.5pp | 31.6%+59.5pp | ||
| -$102.29M-173% | -$117.42M+20.0% | -$214.46M-93.5% | -$160.18M-7.8% | $139.82M+312% |
FAQ
- What is Ionis Pharmaceuticals's revenue?
- Ionis Pharmaceuticals (IONS) generated $874.1M in revenue over the trailing twelve months, down 7.4% year over year.
- Is Ionis Pharmaceuticals profitable?
- Ionis Pharmaceuticals is not currently profitable: it reported a net loss of $565.2M over the trailing twelve months, a -64.7% net margin.
- What are Ionis Pharmaceuticals's profit margins?
- Gross margin is 98.2% and operating margin is -68.0%, with a -64.7% net margin.
- What is Ionis Pharmaceuticals's earnings per share?
- Ionis Pharmaceuticals's diluted EPS over the trailing twelve months is $-3.46.
- Where does Ionis Pharmaceuticals's income statement data come from?
- Every line is extracted from Ionis Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
